中東和非洲膀胱癌診斷市場，按測試類型（膀胱鏡檢查、尿液實驗室測試、活檢、影像學測試等）、分期（I 期、II 期、III 期和 IV 期）、癌症類型（膀胱移行細胞癌、鱗狀細胞膀胱癌和其他癌症類型）、最終用戶（醫院、診斷影像中心、癌症研究機構、獨立診斷實驗室和相關實驗室）、零售項目和市場劃分趨勢
中東和非洲膀胱癌診斷市場分析和規模
中東和非洲膀胱癌診斷市場本質上是分散的，因為它由許多全球參與者組成，例如 F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV 和 Bio-Rad Laboratories, Inc. 等。這些公司的存在使得整個地區的膀胱癌診斷價格具有競爭力。由於這些參與者存在於地區和國際層面，供應商和製造商提供各種預算中具有不同規格和特點的產品。膀胱癌盛行率的上升正在推動市場的成長。此外，人們對膀胱癌早期發現的認識不斷提高預計將推動市場成長。
Data Bridge Market Research 分析稱，中東和非洲膀胱癌診斷市場預計到 2030 年將達到 2.1082 億美元的價值，預測期內的複合年增長率為 6.7%。本市場報告也深入探討了定價分析和技術進步。
|
報告指標 |
細節 |
|
預測期 |
2023年至2030年 |
|
基準年 |
2022 |
|
歷史歲月 |
2021（可自訂為 2015 - 2020 年） |
|
定量單位 |
收入（百萬美元） |
|
涵蓋的領域 |
檢測類型（膀胱鏡檢查、尿液實驗室檢查、活檢、影像學檢查等）、分期（I 期、II 期、III 期和 IV 期）、癌症類型（膀胱移行細胞癌、鱗狀細胞膀胱癌和其他癌症類型）、最終用戶（醫院、診斷影像中心、癌症研究機構、獨立診斷實驗室和相關實驗室）、分銷管道（直接招標和零售） |
|
覆蓋國家 |
南非、沙烏地阿拉伯、阿聯酋、埃及、以色列、中東和非洲其他地區 |
|
涵蓋的市場參與者 |
F. Hoffmann-La Roche Ltd、默克公司、賽默飛世爾科技公司、荷蘭皇家飛利浦公司、Bio-Rad Laboratories, Inc.、安捷倫科技公司、富士膠片公司、佳能醫療系統公司、西門子醫療有限公司、BD、Illumina, Inc.、東軟集團、雅培公司、電氣公司、Hologic Inc. Co. 等 |
市場定義
膀胱癌的發生是由於膀胱內壁的健康細胞（最常見的是尿路上皮細胞）發生變化並失控生長，形成稱為腫瘤的腫塊。尿路上皮細胞也排列在腎盂、輸尿管和尿道內壁。在腎盂和輸尿管發生的癌症也被認為是一種尿路上皮癌，通常被稱為上尿路上皮癌。在大多數情況下，其治療方法與本指南中所述的膀胱癌治療方法大致相同。腫瘤可以是癌性的，也可以是良性的。癌性腫瘤是惡性的，這意味著它可以生長並擴散到身體的其他部位。良性腫瘤意味著腫瘤可以生長但不會擴散。良性膀胱腫瘤非常罕見。
中東和非洲膀胱癌診斷市場動態
本節涉及了解市場驅動因素、優勢、機會、限制和挑戰。所有這些都將在下面詳細討論：
司機
全球膀胱癌發生率上升
大多數與膀胱癌相關的基因突變都是在人類的一生中發生的，而不是在出生前遺傳的。其中一些獲得性基因突變是由於接觸致癌化學物質或輻射造成的。例如，菸草煙霧中的化學物質會被吸收到血液中，經過腎臟過濾，最終進入尿液，進而影響膀胱細胞。其他化學物質也可能以同樣的方式到達膀胱。然而，有時基因變化可能只是隨機事件，有時發生在細胞內部而沒有外在原因。
膀胱癌主要發生在老年人身上。大約有十分之九的膀胱癌患者年齡超過 55 歲。這些患者被診斷出患有膀胱癌時的平均年齡為 73 歲。人群中膀胱癌病例的增加促進了膀胱癌診斷產品的使用，從而推動了膀胱癌診斷市場的成長。
提高對膀胱癌早期診斷的認識
五月是美國全國慶祝膀胱癌宣傳月。其目的是將膀胱腫瘤群體聚集在一起，幫助提高意識，並關注經常被忽視的患者群體。儘管膀胱癌並不像乳癌或肺癌那麼常見，但對治療膀胱腫瘤患者的新方法和創新方法的需求從未如此迫切。研究表明，美國有超過 72 萬名患者正在與膀胱癌作鬥爭。
隨著當前全球健康危機在 COVID-19 的影響下不斷變化，了解患者護理、教育和癌症研究的影響的重要性變得比以往任何時候都更加明顯。展望未來，在為膀胱腫瘤患者發現新的有效藥物方面仍有許多基礎工作要做，同時迫切需要對治療膀胱癌時面臨的眾多挑戰進行持續的教育。
膀胱癌宣傳月是一項完全致力於這些努力的運動，即使在大流行期間，幫助這群患者仍然是重中之重。因此，人們對膀胱癌早期診斷的認識不斷提高，推動了市場的成長。
機會
膀胱癌診斷程序增加
膀胱癌是全球十大常見癌症之一，發病率和死亡率相當高，因此給醫療保健系統帶來了沉重的負擔。用於診斷膀胱癌的幾種技術包括超音波、電腦斷層掃描 (CT)、磁振造影 (MRI)，有時還包括正子斷層掃描 (PET)。
對於生長速度緩慢的膀胱癌，治療可能需要監測。惡性腫瘤的化療有時會與放射療法和幹細胞移植結合。人們更喜歡接受治療和診斷。此外，癌症發生率的上升也是診斷產品獲準增加的一個推動因素。
克制/挑戰
膀胱癌治療藥物和療法的副作用
化學療法（chemo）使用抗癌藥物，通常透過靜脈（IV）注射或口服。這些藥物進入血液並到達身體的幾乎所有部位。然而，許多化療藥物無法進入膀胱並到達腫瘤細胞。卡介苗（BCG）是治療早期膀胱癌最常見的膀胱內免疫療法。 BCG 是一種與引起結核病 (TB) 的細菌有關的細菌，但它通常不會引起嚴重疾病。當 BCG 以液體形式透過導管注入膀胱時，它有助於「啟動」那裡的免疫系統細胞，然後攻擊膀胱癌細胞。
化療藥物可能會引起副作用。這取決於藥物的類型和劑量以及治療持續時間。常見的副作用包括掉髮、口腔潰瘍、食慾不振、噁心嘔吐、腹瀉、感染幾率增加（白血球過少）、容易瘀青或出血（血小板過少）、疲勞（紅血球過少、新陳代謝變化或其他因素）。有些化療藥物還會引起其他不太常見的副作用。例如，順鉑和卡鉑也會導致腎臟損害和聽力損失。有時，可能需要減少藥物劑量，或需要延遲或停止治療，以防止影響變得更糟。因此，膀胱癌治療藥物和療法的副作用可能會抑制中東和非洲膀胱癌診斷市場的成長。
COVID-19 對中東和非洲膀胱癌診斷市場的影響
COVID-19 對中東和非洲膀胱癌診斷市場產生了負面影響。封鎖限制導致各種挑戰的出現，例如就診人數減少和治療程序延遲。
COVID-19 疫情在一定程度上對市場產生了負面影響。然而，政府支持的增加和成像技術的進步預計將為市場成長提供豐厚的機會。此外，預計市場參與者之間不斷增加的夥伴關係、收購和協作將進一步推動市場成長。此外，自新冠疫情爆發後市場開放以來，成長一直很高，預計該產業將實現相當大的成長。市場參與者正在進行多項活動來改善膀胱癌早期發現的影像技術。由此，企業將為市場帶來進步與創新。
最新動態
- 2020年5月，F. Hoffmann-La Roche Ltd正式收購Stratos Genomics。透過此次收購，該公司還將致力於開發用於診斷的基於 DNA 的測序技術。這增強了公司的醫療診斷部門，從而為公司帶來了更多的收入。
- 2023年1月，賽默飛世爾科技公司宣布已完成收購全球專業診斷領域領導者The Binding Site Group的協議。此次收購將有助於專業診斷領域的發展。
中東和非洲膀胱癌診斷市場範圍
中東和非洲膀胱癌診斷市場根據測試類型、階段、癌症類型、最終用戶和分銷管道分為五個顯著的部分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
測試類型
- 膀胱鏡檢查
- 尿液實驗室檢查
- 活檢
- 影像學檢查
- 其他的
根據測試類型，市場分為膀胱鏡檢查、尿液實驗室測試、活檢、影像學測試等。
階段
- 第一階段
- 第二階段
- 第三階段
- 第四階段
根據階段，市場分為第一階段、第二階段、第三階段和第四階段。
癌症類型
- 膀胱移行細胞癌
- 鱗狀細胞膀胱癌
- 其他癌症類型
根據癌症類型，市場分為移行細胞膀胱癌、鱗狀細胞膀胱癌和其他癌症類型。
最終用戶
- 醫院
- 診斷影像中心
- 癌症研究機構
- 獨立診斷實驗室
- 相關實驗室
根據最終用戶，市場細分為醫院、診斷影像中心、癌症研究機構、獨立診斷實驗室和相關實驗室。
分銷管道
- 直接投標
- 零售銷售
根據分銷管道，市場分為直接招標和零售。
中東和非洲膀胱癌診斷市場區域分析/洞察
對中東和非洲膀胱癌診斷市場進行了分析，並按國家、測試類型、階段、癌症類型、最終用戶和分銷管道提供了市場規模洞察和趨勢，如上所述。
本市場報告涉及的國家包括南非、沙烏地阿拉伯、阿聯酋、埃及、以色列、中東其他地區和非洲。
預計南非將佔據市場主導地位並佔據最大市場份額。這一份額歸功於 F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV 和 Bio-Rad Laboratories, Inc. 等主要市場參與者的存在。預計膀胱癌盛行率的上升和成像技術的改進將在預測期內推動該地區市場的成長。
報告的國家部分還提供了影響市場當前和未來趨勢的個別市場影響因素和市場監管變化。下游和上游價值鏈分析、技術趨勢、波特五力分析和案例研究等數據點是用於預測各國市場情景的一些指標。此外，在對國家數據進行預測分析時，還考慮了全球品牌的存在和可用性以及由於來自本地和國內品牌的大量或稀缺的競爭、國內關稅和貿易路線的影響而面臨的挑戰。
競爭格局和中東和非洲膀胱癌診斷市場份額分析
中東和非洲膀胱癌診斷市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、新市場計劃、全球影響力、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度以及應用主導地位。以上提供的數據點僅與公司對市場的關注有關。
中東和非洲膀胱癌診斷市場的一些主要市場參與者包括 F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV、Bio-Rad Laboratories, Inc.、Agilent Technologies, Inc.、FUJIFILM Corporation. Corporation、Abbott、General Electric Company、Hologic Inc.、QIAGEN、Cepheid、Ambu A/S、Time Medical Holding 和 MinFound Medical Systems Co. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT
6 REGULATORY FRAMEWORK
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING INCIDENCE OF BLADDER CANCER MIDDLE EAST & AFRICALY
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS
7.3.3 INCREASE IN THE GERIATRIC POPULATION
7.4 CHALLENGES
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES
8 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 CYSTOSCOPY
8.3 URINE LAB TEST
8.3.1 URINE CYTOLOGY
8.3.2 URINALYSIS
8.3.3 URINE TUMOR MARKER TEST
8.3.4 URINE CULTURE
8.3.5 OTHERS
8.4 BIOPSY
8.5 IMAGING TEST
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.5.3 ULTRASOUND
8.5.4 INTRAVENOUS PYELOGRAM (IVP)
8.6 OTHERS
9 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES
9.1 OVERVIEW
9.2 STAGE IV
9.3 STAGE III
9.4 STAGE II
9.5 STAGE I
10 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 TRANSITIONAL CELL BLADDER CANCER
10.3 SQUAMOUS CELL BLADDER CANCER
10.4 OTHER CANCER TYPES
11 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 DIAGNOSTIC IMAGING CENTERS
11.4 CANCER RESEARCH INSTITUTES
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES
11.6 ASSOCIATED LABS
12 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E
13.1.4 EGYPT
13.1.5 ISRAEL
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET
16.1 F. HOFFMANN- LA ROCHE LTD
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 MERCK KGAA
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 THERMO FISHER SCIENTIFIC INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 KONINLIJKE PHILIPS N.V.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 BIO-RAD LABORATORIES, INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SNAPSHOT
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 AGILENT TECHNOLOGIES, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 AMBU A/S
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BD
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CANON MEDICAL SYSTEMS CORPORATION
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 FUJIFILM CORPORATION
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 GENERAL ELECTRIC COMPANY
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 HOLOGIC INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 ILLUMINA INC
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MINFOUND MEDICAL SYSTEMS CO.,
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 NEUSOFT CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 COMPANY SNAPSHOT
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 QIAGEN
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 SIEMENS HEALTHCARE GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA CYSTOSCOPY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA BIOPSY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA OTHERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA STAGE IV IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA STAGE III IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA STAGE II IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA STAGE I IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA TRANSITIONAL CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA SQUAMOUS CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA OTHER CANCER TYPES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA HOSPITAL IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ASSOCIATED LABS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA DIRECT TENDER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA RETAIL SALES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 35 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 SOUTH AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 SOUTH AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 39 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 40 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 42 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 SAUDI ARABIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 SAUDI ARABIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 46 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 47 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 U.A.E. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 U.A.E. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 52 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 53 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 54 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 55 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 56 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 57 EGYPT URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 58 EGYPT IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 60 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 61 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 63 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 ISRAEL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 ISRAEL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 67 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 68 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 69 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 70 REST OF MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF BLADDER CANCER MIDDLE EAST & AFRICALY IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 CYSTOSCOPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET
FIGURE 14 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2022
FIGURE 19 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 39 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
